American Century Companies Inc. Decreases Stock Position in Edwards Lifesciences Corporation $EW

American Century Companies Inc. lessened its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 6.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 210,331 shares of the medical research company’s stock after selling 14,035 shares during the period. American Century Companies Inc.’s holdings in Edwards Lifesciences were worth $16,357,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. True Wealth Design LLC lifted its stake in shares of Edwards Lifesciences by 251.5% during the 3rd quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock valued at $28,000 after buying an additional 259 shares in the last quarter. Hantz Financial Services Inc. boosted its holdings in Edwards Lifesciences by 76.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock worth $29,000 after buying an additional 164 shares during the period. Rakuten Securities Inc. grew its stake in Edwards Lifesciences by 413.7% in the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock valued at $29,000 after buying an additional 302 shares in the last quarter. Steigerwald Gordon & Koch Inc. bought a new stake in Edwards Lifesciences during the 3rd quarter valued at $30,000. Finally, Strengthening Families & Communities LLC bought a new stake in Edwards Lifesciences during the 3rd quarter valued at $34,000. Institutional investors own 79.46% of the company’s stock.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 11,340 shares of Edwards Lifesciences stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $85.93, for a total transaction of $974,446.20. Following the completion of the sale, the vice president owned 21,266 shares of the company’s stock, valued at $1,827,387.38. The trade was a 34.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $85.70, for a total value of $87,328.30. Following the completion of the transaction, the vice president owned 22,002 shares of the company’s stock, valued at $1,885,571.40. The trade was a 4.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 60,104 shares of company stock worth $5,084,637 in the last 90 days. Company insiders own 0.34% of the company’s stock.

Edwards Lifesciences Trading Up 1.8%

Shares of EW opened at $85.76 on Wednesday. Edwards Lifesciences Corporation has a 1-year low of $65.94 and a 1-year high of $87.89. The company has a market capitalization of $49.81 billion, a P/E ratio of 46.86, a P/E/G ratio of 2.20 and a beta of 0.93. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.72 and a quick ratio of 3.09. The firm’s 50 day simple moving average is $82.50 and its 200 day simple moving average is $81.52.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, February 10th. The medical research company reported $0.58 EPS for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The company had revenue of $1.57 billion during the quarter, compared to analysts’ expectations of $1.54 billion. During the same period in the prior year, the firm earned $0.59 EPS. Edwards Lifesciences’s quarterly revenue was up 13.3% on a year-over-year basis. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Sell-side analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Key Stories Impacting Edwards Lifesciences

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: EW was named among “5 Medical Instruments Stocks to Buy” for near-term upside tied to AI-enabled tools, M&A and new product pipelines — this highlights elevated analyst/market interest in Edwards’ growth catalysts. Zacks: 5 Medical Instruments Stocks to Buy Yahoo: 5 Medical Instruments Stocks to Buy
• Positive Sentiment: Brokerage consensus cited as an average “Moderate Buy,” reinforcing analyst support that can sustain demand for the shares. American Banking News: Moderate Buy
• Positive Sentiment: Recent commentary notes EW has outperformed the S&P 500 and analysts remain moderately optimistic — a sign of relative strength vs. the market that can attract momentum buyers. Barchart: Outperforming the S&P 500
• Neutral Sentiment: Management presented at Barclays’ 28th Annual Global Healthcare Conference (transcript available) — investors should watch for any strategic commentary or forward guidance color, but no headline surprises reported yet. Seeking Alpha: Barclays Presentation Transcript
• Neutral Sentiment: Broader diagnostics and medical-device sector stories (IDXX, DGX, National Vision) point to healthy industry fundamentals and innovation, which can be a supportive backdrop for EW even if the articles aren’t specific to Edwards. Yahoo: IDEXX Yahoo: Quest Diagnostics Yahoo: National Vision
• Negative Sentiment: Short interest rose sharply in February — up ~56.6% vs. mid‑February to ~12.38M shares (about 2.1% of shares outstanding), with a short-interest ratio ~2.7 days. That increase can amplify near-term volatility and create short‑covering squeezes if catalysts reverse. (Data reported 2/27)

Wall Street Analyst Weigh In

A number of research firms have recently commented on EW. Barclays reaffirmed an “overweight” rating and issued a $104.00 price target (up from $103.00) on shares of Edwards Lifesciences in a report on Monday, January 12th. UBS Group reissued a “neutral” rating and set a $94.00 price objective on shares of Edwards Lifesciences in a report on Wednesday, February 4th. BTIG Research restated a “buy” rating and issued a $103.00 target price on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Evercore reaffirmed an “outperform” rating and set a $94.00 target price on shares of Edwards Lifesciences in a report on Monday, January 5th. Finally, JPMorgan Chase & Co. upgraded Edwards Lifesciences from a “neutral” rating to an “overweight” rating and upped their price target for the company from $90.00 to $100.00 in a research report on Thursday, December 18th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $96.14.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.